AIm: Many guidelines recommend carotid endarterectomy (CEA) in symptomatic patients with carotid stenosis of greater than 70%, and carotid artery stenting (CAS) as an alternative to CEA. In our study, we evaluated the clinical characteristics of patients who underwent revascularizaton therapy.
InTRoduCTIon
Despite improvements in diagnosis and management, cerebrovascular diseases are the third leading cause of death following heart diseases and cancer, and the leading cause of long-term disability (30). Stroke survivors still remain at substantial risk of developing subsequent strokes, emphasizing the importance of secondary preventive measures. Ten to thirty percent of ischemic strokes are secondary to emboli from the carotid arteries (3, 10) . In the Framingham Heart Study population, the prevalence of >50% carotid stenosis was 7% in women and 9% in men ranging in age from 66 to 93 years (14) . In the Cardiovascular Health Study of subjects older than 65 years of age, 7% of men and 5% of women had moderate carotid stenosis (50% to 74%); and severe stenosis (75% to 100%) was detected in 2.3% of men and 1.1% of women (2). The odds ratio was reported as 3.3 for patients with symptomatic stenosis compared to other stroke etiologies, and up to 26% overall risk was found in the first 2 years after the initial event in medically treated patients (24) .
During the 1990s, carotid endarterectomy (CEA) was first established as the choice of treatment in carotid stenosis (7, 9, 10) , and many guidelines recommend CEA in symptomatic patients with carotid stenosis of greater than 70% or in
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asymptomatic patients with carotid stenosis of greater than 60% (7, 8, 15, 16) . Accurate assessment of the severity of arterial stenosis is, however, essential to the selection of appropriate patients for surgical or endovascular intervention. Carotid duplex ultrasonography (DUS), computed tomography angiography (CTA), and magnetic resonance angiography (MRA) can provide the information needed to guide the choice of medical, endovascular, or surgical treatment in most cases. Surgery was most effective in patients with >70% carotid stenosis without occlusion or near-occlusion (34) . When the combined outcome of fatal or disabling ipsilateral ischemic stroke, perioperative stroke, or death was considered, the benefit of surgery was evident in patients with 80% to 99% stenosis.
In the last decade, carotid artery stenting (CAS) has emerged as an alternative to CEA for the treatment of carotid artery occlusive disease, and has been endorsed by the American Heart Association/American Stroke Association guidelines as a reasonable strategy when performed by operators with established peri-procedural morbidity and mortality of 4% to 6% (class IIa) (18, 35) . The European Society of Vascular Surgery recommends CAS instead of CEA in participants at high risk for cardiovascular disease if it is conducted in high-volume centers with documented low perioperative stroke and death rates (23) . Although CAS has the advantage of being a lessinvasive procedure, potentially minimizes the risks of wound complications and cranial nerve injury, and shortens the length of hospitalization, the safety and efficacy of CAS are controversial (33) .
Symptomatic occlusions of the vertebral arteries are less commonly encountered in clinical practice. In compared with CEA, operations are rarely performed in vertebral stenosis. There are no randomized trials in the management of vertebral stenosis; although some reports showed good outcomes with surgical treatment (4, 20) , angioplasty and stenting of the vertebral vessels are technically much more feasible with favorable prognosis.
In our study, we aimed to evaluate the clinical characteristics of patients who underwent revascularization therapy, and to investigate the long-term prognosis following endarterectomy versus stenting.
MATERIAL and METHodS
In this retrospective cohort study, we reviewed the files of 2369 patients with stroke followed at our cerebrovascular outpatient clinics since 1996. A total of 2151 patients (90.7%) had ischemic stroke, and 379 of these (17.6%) were diagnosed as having ischemic atherothrombotic stroke due to large artery atherosclerosis according to TOAST criteria, upon a detailed clinical evaluation, physical and neurological examinations, and neuroimaging characteristics (1). The diagnosis of ischemic stroke was established by cranial computed tomography (CT) and/or magnetic resonance imaging (MRI). The diagnosis of large artery atherosclerosis was based on neuroimaging findings by carotid DUS and CTA or MRA; and/or catheter-based contrast angiography, in which either a significant stenosis (>50%) or occlusion was established in carotid or vertebral arteries. The potential causes of cardiogenic embolism were excluded in all patients.
The demographic data and the risk factors of 379 patients were reviewed. Risk factors included gender, age (over 45 years for male and over 55 years or premature menopause needing estrogen replacement therapy for female), smoking, alcohol intake, hypertension (systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg that was recorded in medical files), antihypertensive therapy, presence of cardiac disease, the type of cardiac disease if any, dyslipidemia (blood total cholesterol >200 mg/dl, triglyceride >150 mg/dl, LDL cholesterol ≥100 mg/dL, HDL cholesterol <40 mg/dL), lipidlowering therapy, non-insulin dependent diabetes (fasting blood glucose >140 mg/dl in two consequent measurements or blood glucose level of >200 mg/dl after 75 mg oral glucose tolerance test), antidiabetic therapy, history of previous cerebrovascular disease and the use of anti-thrombotic or anticoagulation therapy.
The decision of revascularization and the choice of the type of intervention were based on the recent guidelines of the era, but also on the patients' and their families' decisions (13,27). We evaluated the pre-and post-Rankin values for patients who underwent revascularization therapy. In addition to other risk factors, the side of the intervention and the presence of occlusion on the opposite artery were also noted. The primary endpoints were set as recurrent transient ischemic attacks (TIA) or stroke, myocardial infarction (MI) including silent MI, peripheral vascular diseases, and deaths due to cardiovascular diseases. The emergence of diseases, and deaths due to other diseases than cardiovascular disorders were the secondary outcomes.
The statistical analyses were performed with the software (version 11.5 for Windows; SPSS, Chicago, IL). Statistical tests used in the analysis were χ2 or Fisher's test for independent categorical variables, Student t test and analysis of variance (ANOVA) for normally distributed independent numerical variables, and Mann-Whitney U and Kruskal-Wallis test for not normally distributed independent numerical variables. The effects of covariates and independent variables on the development of atherothrombotic events were investigated by covariance analysis (ANCOVA) and logistic regression. A p value of >0.05 was considered statistically significant.
RESuLTS
We evaluated the files of 2369 patients with stroke followed in our cerebrovascular outpatient clinics since 1996. Of these, 379 patients were diagnosed as having ischemic atherothrombotic stroke, and 92 of them (24.2%) were treated by revascularization. The clinical characteristics of patients treated with invasive intervention and those with medical therapy are given in Table I . Men were more commonly treated with revascularization therapy (p=0.035), and smoking was more common in this group of patients (p=0.044). All other risk factors were similar in two groups.
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The evaluation of patients with revascularization therapy revealed that 41 patients out of 379 patients with ischemic atherothrombotic stroke received CEA (10.8%), 42 patients had CAS (11%), and only 9 patients had VAS (2.3%). Table II demonstrates the characteristics of patients underwent CEA, CAS or VAS. Hyperlipidemia (p=0.019) was more common in patients underwent CAS, while smoking was more common (p=0.034) in patients having CEA. The history of cardiac diseases and coronary artery disease was observed more common in CEA group, and the history of previous stroke was more common in CAS patients, but these differences did not reach statistically significant level (p>0.05). The other risk factors were similar between CEA and CAS patients.
Seventy-seven patients out of 92 patients with revascularization therapy were followed-up for a mean period of 50.2±42.7 months (varying between 6 and 168 months). The degree of stenosis was higher in patients selected for CAS, though not significant (Table III) . The side of the lesion and the presence of total occlusion in contralateral carotid artery were similar in two groups. The interval between stroke and revascularization was shorter in patients with CAS in compared to patients CEA (49.1±50.3 days versus 72.1±60.6 days respectively, p=0.094), though not statistically significant. The follow-up period was significantly longer in patients with CEA (p=0.026). The preintervention Rankin scores were higher in CAS group, but not significant; while post-intervention Rankin scores or the changes in Rankin scores were similar (Table III) .
Among the primary endpoints, recurrent stroke or TIA and deaths due to cerebrovascular diseases were similar between two groups. The myocardial infarction (including silent MI) and deaths due to cardiovascular diseases were more common in CAS group, though not significant (Table III) . The deaths due to other diseases (such as cancer, accidents…) and other non-fatal complications were significantly more common in CEA patients. On the other hand, restenoses -all of which were radiological findings but asymptomatic -were more common in CAS group (Table III) . 
dISCuSSIon
Here we presented the clinical characteristics and prognosis of patients who underwent revascularization therapy in our stroke unit. Patients selected for CAS had a more severe stenosis and higher Rankin scores, though not significant. The risk factors were mostly similar between two groups, except that smoking was more common in CEA group, and hyperlipidemia was more common in CAS group. The followup period was significantly longer in patients with CEA, as the procedure was performed since 1996, while CAS procedure was performed since 2002. The primary end points in terms of recurrent stroke/TIA, MI and deaths due to cardiovascular complications were similar between two groups. The deaths due to other diseases (such as cancer, accidents…) and other non-fatal complications, however, were significantly more common in CEA patients, while asymptomatic restenosis was significantly more common in CAS group.
In the literature, there are many randomized controlled trials comparing CEA and CAS, though they do not imply how many patients of the stroke population needed revascularization therapy, or the differences in these patients in compared to stroke patients who did not need revascularization. These studies also lack of long-term follow-up, emphasizing the need of more long-term data from stenting versus endarterectomy trials. The first multicenter study was the CAVATAS trial (Carotid and Vertebral Artery Transluminal Angioplasty Study) published in 2001 (31) . Here, both symptomatic and asymptomatic patients were enrolled, and the CAVATAS trial demonstrated no statistically significant difference between the surgery arm and the endovascular arm in the rate of stroke or death within 30 days. The 8-year incidence and hazard ratio at the end of followup for ipsilateral non-perioperative stroke was also found insignificant in two groups, though more patients had stroke during follow-up in the endovascular group than in the surgical group (12) . The SAPPHIRE (Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy) study was the first trial comparing CEA with CAS using distal cerebral protection (22) . There were no demographic or baseline medical history differences between the 2 groups, with the majority of patients being asymptomatic (71%) and approximately 20% of patients being older than 80 years. The primary end point of the study was death, stoke, and MI. The 30-day stroke/death/MI rate was lower in the CAS group (4.8%) than in the CEA group, although not significant. The CaRESS (Carotid Revascularization Using Endarterectomy or Stenting Systems) trial was designed to prove equivalence between CAS with cerebral protection and CEA in symptomatic and asymptomatic patients (9). Similarly, no statistically significant difference was found between the 30-day and 1-year death and stroke rates. The EVA-3S (Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis) trial was designed to assess the noninferiority of CAS versus CEA in low-risk, symptomatic patients (25) . The primary end point was seen in 3.9% of patients undergoing CEA and 9.6% of CAS patients (p<0.01), concluding that CAS was inferior to CEA in patients with symptomatic carotid stenosis more than 60%, with respect to the incidence of stroke and death at 30 days postprocedure. A recent CREST (Carotid Revascularization Endarterectomy Versus Stent Trial) and ICSS (International Carotid Stenting Study) trial with a median follow-up period of 2.5 years showed no significant difference in the estimated 4-year rates of the primary end point. However, analysis of the individual components of the composite end point revealed a periprocedural stroke rate of only 2.3% for CEA and 4.1% for CAS (p<0.01). Mortality was equivalent in both groups, and MI was higher in the surgical group (p=0.03). For patients ≥70 years old, CAS results were slightly better, with a larger benefit for stenting as the younger the age of the patient. ICSS compared the results of CEA and CAS for patients with only symptomatic carotid stenosis and showed that risks of any stroke and all-cause death were higher in the stenting group. The authors concluded that CEA remains the treatment of choice for patients with symptomatic CS who are suitable for surgery.
A recent meta-analysis of 13 randomized clinical trials showed that CAS was associated with an increased risk of periprocedural outcomes of death, MI, or stroke, but with reductions in the risk of MI and cranial nerve injury when compared with CEA. Another meta-analysis of recent three trials showed that perioperative risk of stroke or death was significantly higher with CAS than with CEA (26) . The investigators concluded that CAS for treatment of people with symptomatic carotid artery stenosis should be avoided among people older than 70 years. Data on the safety and potential efficacy of CAS in younger patients were insufficient to draw a conclusion. The currently available periprocedural morbidity/mortality data from several trials have not conclusively shown CAS to be safer than CEA for treatment of either asymptomatic or symptomatic patients. The subsequent risk of ipsilateral stroke appears to be similar with both procedures. However, the long-term durability of CAS has not been established; for example, the rate of recurrent stenosis has not well-established yet. In conclusion, CEA was suggested to remain as the procedure of choice for stroke prevention in patients with severe, symptomatic carotid stenosis (29) . CAS was suggested as a good alternative in symptomatic patients with major medical comorbidities precluding CEA. Each patient's risk of MI and stroke should therefore be considered based on a variety of risk factors, and the treatment should be selected only after a comprehensive discussion with the patient.
For proximal vertebral artery reconstruction, early complication rates of 2.5-25% and perioperative mortality rates of 0-4% have been reported (5, 6) . For distal vertebral artery reconstruction, mortality rates have ranged from 2% to 8% (4, 19, 20, 21, 36) . In a review of 300 interventions for proximal vertebral artery stenosis, the risk of death was 0.3%, the risk of periprocedural neurological complications was 5.5%, and risk of posterior stroke was 0.7% at a mean follow-up of 14.2 months. Restenosis occurred in 26% of cases after a mean of 12 months (range 3 to 25 months), although restenosis was not consistently correlated with recurrent symptoms (11) . When data from 14 case series were combined, the annual stroke risk after angioplasty for distal vertebrobasilar disease was approximately 3%, and rates of stroke and restenosis appeared to be related to ascending (more distal) location and the anatomic complexity of the offending lesion. The benefit of revascularization versus modern aggressive medical therapy has not been established for patients with vertebral artery stenosis yet, awaiting large, randomized clinical trials with longer follow-up periods.
The large, randomized, controlled trials comparing CEA and CAS are of great importance to improve our understandings for handling stroke patients better. However, they do not imply about our attitudes towards centers performing revascularization therapy, or whether every center treating stroke patients could be able to perform this type of procedures. On this context, EVA 3S study has demonstrated that several technical factors potentially related to the risk of complications following revascularization therapy showed important differences among centers with negative or positive influences on the outcome (17, 25) . On the other hand, it could be guiding to comprehend our stroke population that needs revascularization therapy and the outcome of our own centers in order to encourage carotid endarterectomy or stenting therapy. 
